clopidogrel / acetylsalicylic acid

This medicine is authorised for use in the European Union.


DuoPlavin is a medicine used to prevent problems caused by blood clots and hardening of the arteries, such as a myocardial infarction (heart attack), in adults who are already taking both clopidogrel and acetylsalicylic acid (also known as aspirin) as separate tablets. It can be used in the following groups of patients who have a condition known as acute coronary syndrome:

  • patients who have unstable angina (a severe type of chest pain) or who have had a heart attack with no ST-segment elevation (an abnormal reading on the ECG or electrocardiogram), including those who are having a stent (a short tube in an artery to prevent it closing up) inserted as part of a percutaneous coronary intervention (a procedure that unblocks blood vessels of the heart to restore its blood supply);
  • patients being treated for heart attack with ST-segment elevation who are having a percutaneous coronary intervention or for whom the doctor thinks that they would benefit from thrombolytic or fibrinolytic treatment (treatments to dissolve blood clots).

DuoPlavin contains the active substances clopidogrel and acetylsalicylic acid.

This EPAR was last updated on 07/07/2023

Authorisation details

Product details
Agency product number
Active substance
  • clopidogrel
  • Acetylsalicylic acid
International non-proprietary name (INN) or common name
  • clopidogrel
  • acetylsalicylic acid
Therapeutic area (MeSH)
  • Acute Coronary Syndrome
  • Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Sanofi Winthrop Industrie
Date of issue of marketing authorisation valid throughout the European Union
Contact address

82 Avenue Raspail
94250 Gentilly

Product information

30/06/2023 DuoPlavin - EMEA/H/C/001143 - N/0071

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

DuoPlavin is indicated for the secondary prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination medicinal product for continuation of therapy in:

  • Non ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (PCI);
  • ST segment elevation acute myocardial infarction (STEMI) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.

For further information please refer to section 5.1.

Assessment history

How useful was this page?

Add your rating
2 ratings